• Please log in or register to access this feature.

Original Article

You have full text access to this OnlineOpen article

Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB

  1. Nicolaos C. Tassopoulos M.D.1,*,
  2. Riccardo Volpes2,
  3. Giuseppe Pastore3,
  4. Jenny Heathcote4,
  5. Maria Buti5,
  6. Robert D. Goldin6,
  7. Sasha Hawley7,
  8. Judy Barber8,
  9. Lynn Condreay9,
  10. D. Fraser Gray7

Article first published online: 30 DEC 2003

DOI: 10.1002/hep.510290321

Issue

Hepatology

Hepatology

Volume 29, Issue 3, pages 889–896, March 1999

Additional Information

How to Cite

Tassopoulos, N. C., Volpes, R., Pastore, G., Heathcote, J., Buti, M., Goldin, R. D., Hawley, S., Barber, J., Condreay, L. and Gray, D. F. (1999), Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB. Hepatology, 29: 889–896. doi: 10.1002/hep.510290321

Author Information

  1. 1

    Western Attica General Hospital, Athens, Greece

  2. 2

    Divisione di Gastroenterologia, Ospedale S Giovanni, Turin, Italy

  3. 3

    Istituto di Malattie Infettive, Ospedale Consorziale Policlinico, Bari, Italy

  4. 4

    Division of Gastroenterolgy, The Toronto Hospital, Toronto, Canada

  5. 5

    Hospital Valle de Hebron, Barcelona, Spain

  6. 6

    Department of Histopathology, St. Mary's Hospital, London, UK

  7. 7

    Department of Anti-Infective and Hepatitis, Glaxo Wellcome, Greenford, UK

  8. 8

    MDS Statistics, Glaxo Wellcome, Greenford, UK

  9. 9

    Department of Virology, Glaxo Wellcome Inc, Research Triangle Park, NC

*Western Attica General Hospital, 1 Dodecanissou Street, Athens 123 51, Greece. Fax: (30)1-684-4046

Publication History

  1. Issue published online: 30 DEC 2003
  2. Article first published online: 30 DEC 2003
  3. Manuscript Accepted: 26 OCT 1998
  4. Manuscript Received: 20 JUL 1998

Funded by

  • Glaxo Wellcome Research and Development, Greenford, UK

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (152K)

References

  • 1
    The World Health Report. WHO 1998.
  • 2
    Realdi G, Alberti A, Rugge M, Bortolotti F, Tigoli AM, Tremolada F, Rual A. Seroconversion from hepatitis B e antigen to anti HBe in chronic hepatitis B virus infection. Gastroenterology 1980; 79:195–199.MEDLINE
  • 3
    Hoofnagle JH, Dusheiko GM, Seef LB, Jones EA, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med 1981; 94:744–748.MEDLINE
  • 4
    Hadziyannis SJ, Lieberman HM, Karvountzis GG, Shafritz DA. Analysis of liver disease, nuclear HBcAg, DNA viral replication, and hepatitis B virus DNA in liver and serum of HBeAg vs. anti-HBe positive carriers of hepatitis B virus. Hepatology 1983; 3:656–662.MEDLINE
    Direct Link:
  • 5
    Lok AS, Hadziyannis S, Weller IV, Karvountzis MV, Monjardino J, Karayiannis P, Montano L, et al. Contribution of low level HBV replication to continuing inflammatory activity in patients with anti-HBe positive chronic hepatitis B virus infection. Gut 1984; 25:1283–1287.MEDLINE
  • 6
    Brunetto MR, Stemler M, Schodel F, Will H, Ottobrelli A, Rizzetto M, Verme G, et al. Identification of HBV variants which cannot produce pre-core derived HBe Ag and may be responsible for severe hepatitis. Ital J Gastroenterol 1989; 21:151–154.
  • 7
    Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC. Mutation preventing formation of e antigen in patients with chronic HBV infection. 8663) Lancet 1989; 2:588–591.MEDLINE
  • 8
    Brunetto MR, Giarin M, Saracco G, Oliveri F, Calvo P, Capra G, Randone A, et al. Hepatitis B virus unable to secrete e Antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993; 105:845–850.MEDLINE
  • 9
    Laras A, Koskinas J, Avgidis K, Hadziyannis SJ. Incidence and clinical significance of hepatitis B virus precore gene translation initiation mutations in e antigen-negative patients. J Viral Hepatitis 1998; 5:241–248.
    Direct Link:
  • 10
    Brunetto MR, Olivieri F, Rocca G, Criscuolo D, Chiaberge E, Capalbo M, David E, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e Antigen. Hepatology 1989; 10:198–202.MEDLINE
    Direct Link:
  • 11
    Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988; 8:493–496.MEDLINE
    Direct Link:
  • 12
    Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, Realdi G, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut 1991; 32:294–298.MEDLINE
  • 13
    Hadziannis SJ. Hepatitis B e antigen negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepatitis 1995; 1:7–36.
  • 14
    Lindh M, Horal P, Dhillon AP, Furata Y, Norkrans G. Hepatitis B virus carriers without pre-core mutations in hepatitis B e antigen-negative stage show more severe liver damage. Hepatology 1996; 24:494–501.MEDLINE
    Direct Link:
  • 15
    Lok ASF, Akarca US, Greene S. Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pregenome encapsidation signal. Proc Natl Acad Sci U S A 1994; 91:4077–4081.MEDLINE
  • 16
    Li JS, Tong SP, Wen YM, Vitvitski L, Zhang Q, Trepo C. Hepatitis B genotype A rarely circulates as an HBe-minus mutant: possible contribution of a single nucleotide in the precore region. J Virol 1993; 67:5402–5410.MEDLINE
  • 17
    Wong DKH, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993; 119:312–23.MEDLINE
  • 18
    Dusheiko GM. Treatment and prevention of chronic viral hepatitis. Pharmacol Ther 1995; 65:47–73.MEDLINE
  • 19
    Pastore G, Santantonio T, Milella M, Monno L, Mariano N, Moschetta R, Pollice L. Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. J Hepatol 1992; 14:221–225.MEDLINE
  • 20
    Zhang X, Zoulim F, Habersetzer F, Xiong S, Trepo C. Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B. J Med Virol 1996; 48:8–16.MEDLINE
    Direct Link:
  • 21
    Tyrell DLJ, Mitchell MC, De Man RA, Schalm SW, Main J, Thomas HC, Fevery J, et al. Phase II trial of lamivudine for chronic hepatitis B [Abstract]. Hepatology 1993; 18(Suppl):112A.
  • 22
    Lai CL, Ching CK, Tung AKM, Li E, Young J, Hill A, Wong BC, et al. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial. Hepatology 1997; 25:241–244.MEDLINE
    Direct Link:
  • 23
    Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995; 333:1657–1661.MEDLINE
  • 24
    Nevens F, Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan M, Fevery J, et al. Lamivudine therapy for chronic hepatitis B: a six-month randomized dose ranging study. Gastroenterology 1997; 113:1258–1263.MEDLINE
  • 25
    Lai CL, Chien R-N, Leung NWY, Chang T-T, Guan R, Tai D-I, Ng K-Y, et al. Lamivudine therapy for chronic hepatitis B: a 12 month double-blind, placebo-controlled multicenter study. N Engl J Med 1998; 339:61–68.MEDLINE
  • 26
    Allen MI, Deslauriers M, Andrews CW, Baldanti F, Tipples GA, Walters KA, Tyrrell DLY, et al. Identification and biologic characterization of mutations in HBV resistant to lamivudine [Abstract]. Hepatology 1997; 26(Suppl):430A.
  • 27
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernon TW, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1:431–435.MEDLINE
    Direct Link:
  • 28
    Lindsay KL. Therapy of hepatitis C: overview. Hepatology 1997; 26(Suppl):71S–77S.MEDLINE
    Direct Link:
  • 29
    Goldin RD, Goldin JG, Burt AD, Dhillon PA, Hubscher S, Wyatt J, Patel N. Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J Hepatol 1996; 25:649–654.MEDLINE
  • 30
    Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaioannou C. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B. J Hepatol 1990; 11(Suppl):S133–S136.MEDLINE
  • 31
    Fattovich G, Farci P, Rugge M, Brollo L, Mandas A, Pontisso P, Giustina G, et al. A randomized controlled trial of lymphoblastoid interferon-α in patients with chronic hepatitis B lacking HB e Ag. Hepatology 1992; 15:584–589.MEDLINE
    Direct Link:
  • 32
    Lampertico P, Del Ninno E, Manzin A, Donato MF, Rumi MG, Lunghi G, Morabito A, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997; 26:1621–1625.MEDLINE
    Direct Link:
  • 33
    Dienstag J, Schiff E, Wright T, Perrillo R, Hann H-W, Crowther L, Woessner M, et al. Lamivudine treatment for one year in previously untreated U.S. hepatitis B patients: histologic improvement and hepatitis B e-antigen (HBeAg) seroconversion [Abstract]. Gastroenterology 1998; 114:1235.
  • 34
    Heathcote J, Schalm SW, Cianciara J, Farrell G, Feinmann V, Shermann M, Dhillon AP, et al. Lamivudine and Intron A combination treatment in patients with chronic hepatitis B infection [Abstract]. J Hepatol 1998; 28:43.
  • 35
    Fischer KP, Tyrrell DLJ. Generation of duck hepatitis B virus polymerase mutants through site-directed mutagenesis which demonstrate resistance to lamivudine [(-)-β-l-2′,3′-dideoxy-3′-thiacytidine] in vitro. Antimicrob Agents Chemother 1996; 40:1957–1960.MEDLINE
  • 36
    Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996; 24:711–713.MEDLINE
    Direct Link:
  • 37
    Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 1996; 24:714–717.MEDLINE
  • 38
    Bartholemew M, Jansen R, Jeffers L, Reddy K, Johnson L, Bunzendahl H, Condreay L, et al. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997; 349:20–22.MEDLINE
  • 39
    Honkoop P, De Man RA, Niesters HGM, Schalm SW. Incidence, characteristics and clinical impact of lamivudine resistance in chronic hepatitis B [Abstract]. J Hepatol 1998; 28:48A.
  • 40
    Melegari M, Scaglioni PP, Wands JR. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27:628–633.MEDLINE
    Direct Link:
  • 41
    Allen MI, Deslauriers M, Andrews W, Tipples GA, Walters K-A, Tyrrell DLY, Brown N, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology 1998; 27:1670–1677.MEDLINE
    Direct Link:
Get PDF (152K)